Puma Historical Income Statement
| PBYI Stock | USD 3.79 0.06 1.56% |
Historical analysis of Puma Biotechnology income statement accounts such as EBITDA of 47 M, Total Operating Expenses of 153.3 M, Income Before Tax of 23.8 M or Net Income of 22.7 M can show how well Puma Biotechnology performed in making a profits. Evaluating Puma Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Puma Biotechnology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Puma Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Puma Biotechnology is a good buy for the upcoming year.
Puma |
About Puma Income Statement Analysis
Puma Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Puma Biotechnology shareholders. The income statement also shows Puma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Puma Biotechnology Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Puma Biotechnology. It is also known as Puma Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Puma Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Total Operating Expenses is estimated to increase to about 153.3 M, while Other Operating Expenses is projected to decrease to under 174.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 10.6M | 8.9M | 10.2M | 9.1M | Interest Income | 160K | 813K | 2.4M | 1.5M |
Puma Biotechnology income statement Correlations
Click cells to compare fundamentals
Puma Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Puma Biotechnology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 15M | 14.1M | 12.8M | 11.5M | 13.3M | 14.0M | |
| Other Operating Expenses | 311.4M | 255.5M | 251.9M | 197.3M | 202.4M | 174.6M | |
| Operating Income | (39.1M) | (30.4M) | (8.9M) | 23.7M | 33.3M | 34.9M | |
| Ebit | (39.1M) | (30.4M) | (8.9M) | 23.7M | 33.3M | 34.9M | |
| Ebitda | (36.1M) | (29.5M) | 1.7M | 31.5M | 44.8M | 47.0M | |
| Total Operating Expenses | 274.6M | 216.1M | 188.2M | 142.2M | 139.7M | 153.3M | |
| Income Before Tax | (75.6M) | (59.8M) | (28.8M) | 500K | 22.7M | 23.8M | |
| Net Income | (82.7M) | (60M) | (29.1M) | 912K | 21.6M | 22.7M | |
| Selling General Administrative | 140.5M | 118.5M | 116.3M | 90.0M | 88.4M | 65.7M | |
| Depreciation And Amortization | 3M | 900K | 10.6M | 7.8M | 11.5M | 12.1M | |
| Total Revenue | 272.3M | 225.1M | 253.2M | 228M | 235.6M | 126.3M | |
| Gross Profit | 235.5M | 185.7M | 189.5M | 172.9M | 173.0M | 101.1M | |
| Net Income From Continuing Ops | (75.6M) | (60.0M) | (29.1M) | 2K | 3.7M | 3.9M | |
| Research Development | 132.9M | 97.7M | 71.9M | 52.2M | 50.4M | 47.9M | |
| Cost Of Revenue | 36.8M | 39.4M | 63.7M | 55.1M | 62.7M | 65.8M | |
| Non Operating Income Net Other | (21.5M) | (15.3M) | (17.3M) | (11.7M) | (10.5M) | (10.0M) | |
| Total Other Income Expense Net | (36.5M) | (29.4M) | (19.9M) | (23.2M) | (10.6M) | (11.1M) | |
| Net Income Applicable To Common Shares | (75.6M) | (60.0M) | (29.1M) | 2K | 2.3K | 2.4K | |
| Income Tax Expense | 7.1M | 200K | 300K | 500K | 1.1M | 1.1M | |
| Net Interest Income | (12.2M) | (13.6M) | (12.6M) | (10.8M) | (10.9M) | (11.4M) | |
| Interest Income | 2.8M | 500K | 160K | 813K | 2.4M | 1.5M | |
| Reconciled Depreciation | 8.1M | 10.0M | 10.6M | 8.9M | 10.2M | 9.1M | |
| Selling And Marketing Expenses | 1.2M | 88K | 6K | 22K | 881K | 925.1K |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Puma Stock
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.78) | Earnings Share 0.32 | Revenue Per Share 4.769 | Quarterly Revenue Growth (0.17) | Return On Assets 0.081 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.